Renal clearance of branched-chain L-amino and 2-oxo acids in maple syrup urine disease

Journal of Inherited Metabolic Disease

Volumn 22, Issue 6, 1999, Pages

  Schadewaldt, P ^a,b   Hammen, H W ^a   Ott, A C ^a   Wendel, U ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOISOCAPROIC ACID; 2 OXOISOVALERATE DEHYDROGENASE (LIPOAMIDE); 2 OXOISOVALERIC ACID; ALLOISOLEUCINE; BRANCHED CHAIN AMINO ACID; ISOLEUCINE; LEUCINE; VALINE;

ACYLATION; ADOLESCENT; ADULT; AMINO ACID BLOOD LEVEL; AMINO ACID URINE LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; HUMAN; KIDNEY CLEARANCE; MAPLE SYRUP URINE DISEASE; SCHOOL CHILD;

ADOLESCENT; ADULT; AMINO ACIDS, BRANCHED-CHAIN; CHILD; CHILD, PRESCHOOL; HUMANS; ISOLEUCINE; KETO ACIDS; LEUCINE; MALE; MAPLE SYRUP URINE DISEASE; METABOLIC CLEARANCE RATE; MIDDLE AGED; VALINE;

EID: 0032771536     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005540016376     Document Type: Article

References (38)

1. Brodehl J, Gellissen K, Jäkel A (1968) Endogenous renal transport of free amino acids in infancy and childhood. Pediatrics 42: 395-404.
2. Chuang DT, Shih VE (1995) Disorders of branched chain amino acid and keto acid metabolism. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1239-1278.
3. Cockroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41.
4. Dancis J, Levitz M, Westall RG (1960) Maple syrup urine disease: branched-chain ketoaciduria. Pediatrics 25: 72-79.
5. Fernhoff PM, Lubitz D, Danner DJ, et al (1985) Thiamine response in maple syrup urine disease. Pediatr Res 19: 1011-1016.
6. Ghazali S, Barrat TM (1974) Urinary excretion of calcium and magnesium in children. Arch Dis Child 49: 97-101.
7. Hagenfeld L, Naglo AS (1987) New conjugated urinary metabolites in intermediate type of maple syrup disease. Clin Chim Acta 169: 77-84.
8. Hayashi T, Tsuchiya H, Naruse H (1983) The stabilization of α-keto acids in biological samples using hydrazide gel column treatment. Clin Chim Acta 132: 321-325.
9. Hill RL (1965) Hydrolysis of proteins. Adv Protein Chem 20: 37-107.
10. Hoffer LJ, Taveroff A, Robitaille L, Mamer OA, Reimer MLJ (1993) α-Keto and α-hydroxy branched-chain acid interrelationship in normal humans. J Nutr 123: 1513-1521.
11. Jakobs C, Solem E, Ek J, Halvorsen K, Jellum E (1977) Investigation of the metabolic pattern in maple syrup urine disease by means of glass capillary gas chromatography and mass spectrometry. J Chromatogr 143: 31-38.
12. Kampmann J, Siersbaek-Nielsen K, Kristensen M, Hansen M (1974) Rapid evaluation of creatinine clearance. Acta Med Scand 196: 517-520.
13. Lancaster G, Mamer OA, Scriver CR (1974) Branched-chain alpha-keto acids isolated as oxime derivatives: relationship to the corresponding hydroxy acids and amino acids in maple syrup urine disease. Metabolism 23: 257-265.
14. Langenbeck U (1984) Pathobiochemical and pathophysiological analysis of the MSUD phenotype. In Adibi SA, Fekl W, Langenbeck U, Schauder P, eds. Branched Chain Amino and Keto Acids in Health and Disease. Basel: S Karger, 315-334.
15. Langenbeck U, Wendel U, Mench-Hoinowski A, et al (1978) Correlations between branched-chain amino acids and branched-chain α-keto acids in blood in maple syrup urine disease. Clin Chim Acta 88: 283-291.
16. Langenbeck U, Wendel U, Luthe H (1979) Renal clearance of branched-chain 2-oxo acids in maple syrup urine disease. J Clin Chem Clin Biochem 17: 176.
17. Lehnert W, Werle E (1988) Elevated excretion of N-acetylated branched-chain amino acids in maple syrup urine disease. Clin Chim Acta 172: 123-126.
18. Livesey G, Edwards WTE (1985) Quantification of branched-chain α-keto acids as quinoxalinols: importance of excluding oxygen during derivatization. J Chromatogr 337: 98-102.
19. Menkes JH (1959) Maple syrup urine disease. Isolation and identification of organic acids in the urine. Pediatrics 23: 348-353.
20. Poole RC, Halestrap AP (1993) Transport of lactate and other monocarboxylates across mammalian plasma membranes. Am J Physiol 264: C761-C782.
21. Price NT, Jackson VN, Halestrap AP (1998) Cloning and sequencing of four mammalian monocarboxylate transporter (MCT) homologues confirms the existence of a transporter family with an ancient past. Biochem J 329: 321-328.
22. Rossi R, Danzebrink S, Linnebürger K, et al (1994) Assessment of tubular reabsorption of sodium, glucose, phosphate and amino acids based on spot urine samples. Acta Paediatr 83: 1282-1286.
23. Schadewaldt P, Hummel W, Trautvetter U, Wendel U (1989) A convenient enzymatic method for the determination of 4-methyl-2-oxopentanoate: comparison with high performance liquid chromatographic analysis. Clin Chim Acta 183: 171-182.
24. Schadewaldt P, Hammen H-W, Dalle-Feste C, Wendel U (1990) On the mechanism of L-alloisoleucine formation : studies on a healthy subject and in fibroblasts from normals and patients with maple syrup urine disease. J Inher Metab Dis 13: 137-150.
25. Schadewaldt P, Wendel U, Hammen H-W (1996) Determination of R- and S-3-methyl-2-oxopentanoate enantiomers in human plasma: suitable method for label enrichment analysis. J Chromatogr B 682: 209-218.
26. 13C]leucine breath tests: a reappraisal in maple syrup urine disease patients, obligate heterozygotes, and healthy subjects. Pediatr Res 43: 592-600.
27. Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58: 259-263.
28. Shigematsu Y, Kikuchi K Momoi T, et al (1983) Organic acids and branched-chain amino acids in body fluids before and after multiple exchange transfusions in maple syrup urine disease. J Inher Metab Dis 6: 183-189.
29. Snyderman SE, Goldstein F, Sansariq C, Norton PM (1984) The relationship between the branched chain amino acids and their α-ketoacids in maple syrup urine disease. Pediatr Res 18: 851-853.
30. Steiner RW (1984) Interpreting the fractional excretion of sodium. Am J Med 77: 699-702.
31. Thompson GN, Bresson JL, Pacy PJ, et al (1990a) Protein and leucine metabolism in maple syrup urine disease. Am J Physiol 258: E654-E660.
32. Thompson GN, Chalmers RA, Halliday D (1990b) The contribution of protein catabolism to metabolic decompensation in 3-hydroxy-3-methylglutaric aciduria. Eur J Pediatr 149: 346-350.
33. Thompson GN, Walter JH, Leonard JV, Halliday D (1990c) In vivo enzyme activity in inborn errors of metabolism. Metabolism 39: 799-807.
34. Thompson GN, Francis DEM, Halliday D (1991) Acute illness in maple syrup urine disease: dynamics of protein metabolism and implications for management. J Pediatr 119: 35-41.
35. Treacy E, Clow CL, Reade TR, Chitayat D, Mamer OA, Scriver CR (1992) Maple syrup urine disease : interrelations between branched-chain amino, oxo- and hydroxyacids; implications for treatment, associations with CNS demyelination. J Inher Metab Dis 15: 121-135.
36. Wahlefeld AW, Siedel J (1985) Creatine and creatinine. In Bergmeyer HU, ed. Methods in Enzymatic Analysis, vol VII. Weinheim: Verlag Chemie, 488-506.
37. Wendel U, Even G, Langenbeck U, Schadewaldt P, Hummel W (1992) Determination of (S)-and (R)-2-oxo-3-methylvaleric acid in plasma of patients with maple syrup urine disease. Clin Chim Acta 208: 85-91.
38. Yu Y-M, Young VR, Castillo L, et al (1995) Plasma arginine and leucine kinetics and urea production rates in burn patients. Metabolism 44: 659-666.